OpenNashPodcasts

Person

Dan Carpenter

1 episodes · 9 quoted claims

Dan Carpenter says the U.S. Food and Drug Administration requires drugmakers to prove effectiveness as well as safety and non-toxicity.

“The FDA wants you to prove not simply that it's safe and non-toxic, but also that it's effective.”

Microsoft Research Podcast · 0:03:17

Dan Carpenter describes the FDA as a veto player that controls which drugs can enter the U.S. market.

“it stands as what I would call the veto player over R &D to the marketplace. The FDA basically has sort of this control over entry to the marketplace.”

Microsoft Research Podcast · 0:04:01

According to Dan Carpenter, phase two drug trials focus mainly on safety with some attention to efficacy, in people who have the disease.

“Then there's a set of phase two trials where they look more at safety and a little bit at efficacy.”

Microsoft Research Podcast · 0:04:01

Dan Carpenter says phase three trials are large randomized clinical trials assessing efficacy and are very expensive for companies.

“phase three involves a much more direct and large-scale attack if you will or assessment of efficacy and that's where you get the sort of large randomized clinical trials that are very expensive”

Microsoft Research Podcast · 0:04:33

Dan Carpenter says many countries, especially in Europe, long waited for the FDA to mandate drug tests before approving drugs themselves.

“a number of other countries, especially in Europe, but around the world, basically waited for the FDA to mandate tests on a drug.”

Microsoft Research Podcast · 0:05:30

Dan Carpenter says the European Medicines Agency became more stringent after the European Union was formed and the agency was created.

“after the formation of the European Union and the creation of the European Medicines Agency, gradually the European Medicines Agency began to get a bit more stringent.”

Microsoft Research Podcast · 0:06:07

Dan Carpenter explains that surrogate endpoints, such as tumor measurements, are used for cancer drugs because waiting to see who survives longer can delay decisions.

“the idea is that a cancer drug, we really want to know whether that drug saves lives. But if we wait to see whose lives are saved or prolonged by that drug, we might miss the opportunity”

Microsoft Research Podcast · 0:08:02

Dan Carpenter says FDA approval covers a drug together with its dosage frequency and method of administration, which trials help establish.

“it's not simply a drug that's approved. It's a drug and a frequency of administration. It's a method of administration.”

Microsoft Research Podcast · 0:12:16

Dan Carpenter says clinical trials are run by companies, not by the FDA, contrary to a common belief.

“Well, some people tend to think that the FDA performs them. It's companies that do it.”

Microsoft Research Podcast · 0:13:50